CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Matthias Alder

Former CEO, Gain Therapeutics

Search every verified Matthias Alder interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Matthias Alder, CEO of Gain Therapeutics, has been discussing the company's computational drug discovery platform and its lead candidate, GT2287, in interviews and podcasts. He described Gain as a computational drug discovery company focused on allosteric modulation, a targeting approach that identifies binding sites on proteins outside the active site. Alder stated that GT2287 is being developed for Parkinson's disease in patients with a mutation of the GBA1 gene, which causes a misfolded and dysfunctional GCase protein. He said preclinical data presented at a Parkinson's conference in Copenhagen showed the drug restored GCase function, reduced toxic materials, improved survival of dopaminergic neurons, and lowered levels of neurofilament light chain in animal models. Alder noted that the company was preparing to begin Phase 1 clinical studies for GT2287 later in 2023. Alder also discussed his leadership approach and the company's transition from preclinical to clinical stage. He described his mindset as having "nothing to hide, nothing to fear, nothing to prove," attributing this to his 30 years of experience in the life sciences. He emphasized the importance of collaboration over competition within the industry, stating that companies should view each other as part of a larger effort rather than as rivals. Alder mentioned that Gain's platform aims to address the roughly 90% of proteins considered undruggable by traditional methods, and he highlighted the company's focus on developing an oral formulation of GT2287 for patient convenience.

Recent appearances

  • Gain Therapeutics: Focused on developing new medicines for protein misfolding diseases

    September 11, 2023 · 📺 LilaMax Media

    Jane King interviews Matthias Alder, CEO of Gain Therapeutics. https://www.gaintherapeutics.com Innovators with Jane King profiles tech companies and thought leaders in the space. We're showing you a glimpse of the future. OVERVIEW LEADING THE DISCOVERY of Allosteric Binding Sites to Create New Medicines Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misf…

    Watch on YouTube ↗

  • Reshaping Misfolding Enzymes

    August 04, 2023 · 📺 Dementia Researcher

    Dr Sam Moxon has been working on a new grant and exploring how to create a spin out innovation biotech company. This work led him to meet Matthias Alder, who we just had to get on the podcast. In this show we hear from Gain Therapeutics CEO Matthias Alder. He is leading a biotech company engaged in the development of a potentially disease-modifying therapy for the treatment of neurodegenerative diseases. Hoping to unlock new treatments for difficult to treat disorders with their SEE-Tx™ supercomputer-driven, drug discovery platform targeting allosteric binding sites. There is a lot of work un…

    Watch on YouTube ↗

  • Computational Drug Discovery With Gain Therapeutics Matthias Alder

    January 27, 2023 · 📺 Gain Therapeutics

    00:00 Matt Pillar: A few months ago.. 01:10 Matthias Alder: Thanks for having me.. 01:15 Matt Pillar: It's a pleasure to have.. 01:54 Matthias Alder 01:56 Matt Pillar 02:15 Matthias Alder 02:40 Matt Pillar 03:00 Matthias Alder 04:25 Matt Pillar 04:40 Matthias Alder 05:36 Matt Pillar 05:48 Matthias Alder 05:49 Matt Pillar 06:26 Matthias Alder 08:50 Matt Pillar 9:50 Matthias Alder 11:08 Matt Pillar 11:16 Matthias Alder 11:18 Matt Pillar 11:23 Matthias Alder 11:25 Matt Pillar 11:42 Matthias Alder 14:09 Matt Pillar 14:10 Matthias Alder 14:41 Matt Pillar 16:05 Matthias Alder 16:06…

    Watch on YouTube ↗

  • Nothing to Hide, Fear or Prove – with Matthias Alder

    January 15, 2023 · 📺 Brilliance Within Coaching

    Matthias Alder, CEO of Gain Therapeutics, is in a unique position. He took over the role of CEO in 2022 from someone who remains a board member at Gain and is a close mentor and ally. Because of these circumstances and Matthias’ 30 years of experience he approaches his leadership with nothing to hide, nothing to fear and nothing to prove. His sole motivation is to align his team and industry collaborators to deliver life saving therapies to patients. In this in-depth conversation, you’ll learn the keys to having a relaxed disposition as CEO and the elements needed to bring out the best in you…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →